Cargando…
Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials
AIM: Bevacizumab and ramucirumab are antiangiogenic monoclonal antibodies, which target vascular endothelial growth factor-A and vascular endothelial growth factor receptor-2, respectively, used in various cancers. Bleeding events have been described with these two agents. We conducted an up-to-date...
Autores principales: | Xiao, Bingkun, Wang, Weilan, Zhang, Dezhi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110629/ https://www.ncbi.nlm.nih.gov/pubmed/30174444 http://dx.doi.org/10.2147/OTT.S166151 |
Ejemplares similares
-
Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab
por: Arnold, D, et al.
Publicado: (2017) -
Monitoring Monoclonal Antibody Delivery in Oncology: The Example of Bevacizumab
por: Nugue, Guillaume, et al.
Publicado: (2013) -
Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report
por: Yamada, Ryo, et al.
Publicado: (2019) -
Assessing the risk-benefit profile of ramucirumab in patients with advanced solid tumors: A meta-analysis of randomized controlled trials
por: Effing, Sophie Marie Anne, et al.
Publicado: (2020) -
The characterization of a novel monoclonal antibody against CD93 unveils a new antiangiogenic target
por: Orlandini, Maurizio, et al.
Publicado: (2014)